Skip to main content
. 2021 Nov 25;9(4):191. doi: 10.3390/pharmacy9040191

Table 2.

Outcomes.

Outcomes All Patients
(n = 193)
Intervention
(n = 110)
Control
(n = 83)
p a
Clinical outcomes
In-hospital mortality 17 (8.8) 4 (3.6) 13 (15.7) 0.0033
Seven-day mortality 14 (7.3) 4 (3.6) 10 (12.1) 0.026
Thirty-day mortality 25 (13.0) 8 (7.3) 17 (20.5) 0.007
Mean length of stay (days) 10.4 10.6 10.2 0.72
Mean duration of antibiotics (days) 27.7 28.3 27.0 0.57
Time to definitive therapy (hours) 17.2 11.7 24.5 0.0011
Time to defervescence (hours) 35.5 31.5 40.9 0.49
Bundle compliance
Overall compliance 109 (56.5) 76 (69.1) 33 (39.8) <0.001
Infectious disease consult 181 (93.4) 108 (98.2) 73 (88.0) 0.003
Appropriate definitive therapy 161 (83.4) 104 (94.5) 57 (68.7) <0.001
Source identified 154 (79.8) 94 (85.5) 60 (72.3) 0.025
Repeat blood cultures collected 181 (93.8) 110 (100) 71 (85.5) <0.001
Echocardiogram performed 161 (83.4) 96 (87.3) 65 (85.5) 0.1
Appropriate duration of antibiotics 161 (83.4) 99 (90) 62 (74.7) 0.005

Data are presented as number of patients (%) unless specified otherwise. Time points refer to time of culture collection as baseline. a p is for intervention vs. control.